Literature DB >> 33398458

Development of sustainable research excellence with a global perspective on infectious diseases: Centre de Recherches Médicales de Lambaréné (CERMEL), Gabon.

Michael Ramharter1,2,3, Selidji T Agnandji4,5,6, Ayôla A Adegnika4,5,6,7, Bertrand Lell4,8, Ghyslain Mombo-Ngoma9,4,10, Martin P Grobusch11, Matthew McCall4, Riko Muranaka9,12, Andrea Kreidenweiss5,6, Thirumalaisamy P Velavan5,6, Meral Esen5,6, Frieder Schaumburg13, Abraham Alabi4, Christiane Druml8, Benjamin Mordmüller5,6, Carsten Köhler5,6, Peter G Kremsner4,5,6.   

Abstract

Medical research in sub-Saharan Africa is of high priority for societies to respond adequately to local health needs. Often enough it remains a challenge to build up capacity in infrastructure and human resources to highest international standards and to sustain this over mid-term to long-term periods due to difficulties in obtaining long-term institutional core funding, attracting highly qualified scientists for medical research and coping with ever changing structural and political environments. The Centre de Recherches Médicales de Lambaréné (CERMEL) serves as model for how to overcome such challenges and to continuously increase its impact on medical care in Central Africa and beyond. Starting off as a research annex to the Albert Schweitzer Hospital in Lambaréné, Gabon, it has since then expanded its activities to academic and regulatory clinical trials for drugs, vaccines and diagnostics in the field of malaria, tuberculosis, and a wide range of poverty related and neglected tropical infectious diseases. Advancing bioethics in medical research in Africa and steadily improving its global networks and infrastructures, CERMEL serves as a reference centre for several international consortia. In close collaboration with national authorities, CERMEL has become one of the main training hubs for medical research in Central Africa. It is hoped that CERMEL and its leitmotiv "to improve medical care for local populations" will serve as an inspiration to other institutions in sub-Saharan Africa to further increase African capacity to advance medicine.

Entities:  

Keywords:  Capacity development; Gabon; Medical research; Neglected tropical diseases; Sub-Saharan Africa

Mesh:

Year:  2021        PMID: 33398458      PMCID: PMC7781170          DOI: 10.1007/s00508-020-01794-8

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  93 in total

1.  Comparison of micronized halofantrine with chloroquine-antibiotic combinations for treating Plasmodium falciparum malaria in adults from Gabon.

Authors:  P G Kremsner; E Wildling; L Jenne; W Graninger; U Bienzle
Journal:  Am J Trop Med Hyg       Date:  1994-06       Impact factor: 2.345

2.  Plasmodium falciparum-malaria: resistance to chloroquine, but sensitivity to mefloquine in the Gabon. A prospective in-vitro study.

Authors:  G D Burchard; R D Horstmann; W H Wernsdorfer; M Dietrich
Journal:  Tropenmed Parasitol       Date:  1984-03

3.  Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children.

Authors:  B Lell; D Luckner; M Ndjavé; T Scott; P G Kremsner
Journal:  Lancet       Date:  1998-03-07       Impact factor: 79.321

4.  Clindamycin in combination with chloroquine or quinine is an effective therapy for uncomplicated Plasmodium falciparum malaria in children from Gabon.

Authors:  P G Kremsner; S Winkler; C Brandts; S Neifer; U Bienzle; W Graninger
Journal:  J Infect Dis       Date:  1994-02       Impact factor: 5.226

5.  High efficacy of short-term quinine-antibiotic combinations for treating adult malaria patients in an area in which malaria is hyperendemic.

Authors:  W Metzger; B Mordmüller; W Graninger; U Bienzle; P G Kremsner
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

6.  Curing of chloroquine-resistant malaria with clindamycin.

Authors:  P G Kremsner; S Winkler; C Brandts; W Graninger; U Bienzle
Journal:  Am J Trop Med Hyg       Date:  1993-11       Impact factor: 2.345

7.  Atovaquone and proguanil for Plasmodium falciparum malaria.

Authors:  P D Radloff; J Philipps; M Nkeyi; D Hutchinson; P G Kremsner
Journal:  Lancet       Date:  1996-06-01       Impact factor: 79.321

8.  Sulfadoxine/pyrimethamine or chloroquine/clindamycin treatment of Gabonese school children infected with chloroquine resistant malaria.

Authors:  W Metzger; B Mordmüller; W Graninger; U Bienzle; P G Kremsner
Journal:  J Antimicrob Chemother       Date:  1995-10       Impact factor: 5.790

Review 9.  Atovaquone and proguanil hydrochloride for treatment of malaria.

Authors:  P G Kremsner; S Looareesuwan; J D Chulay
Journal:  J Travel Med       Date:  1999-05       Impact factor: 8.490

10.  Quinine plus clindamycin improves chemotherapy of severe malaria in children.

Authors:  P G Kremsner; P Radloff; W Metzger; E Wildling; B Mordmüller; J Philipps; L Jenne; M Nkeyi; J Prada; U Bienzle
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

View more
  6 in total

1.  Assessment of malaria transmission intensity and insecticide resistance mechanisms in three rural areas of the Moyen Ogooué Province of Gabon.

Authors:  Stravensky Térence Boussougou-Sambe; Tamirat Gebru Woldearegai; Ange Gatien Doumba-Ndalembouly; Barclaye Ngossanga; Romuald Beh Mba; Jean Ronald Edoa; Jeannot Fréjus Zinsou; Yabo Josiane Honkpehedji; Ulysse Ateba Ngoa; Jean Claude Dejon-Agobé; Steffen Borrmann; Peter G Kremsner; Benjamin Mordmüller; Ayôla A Adegnika
Journal:  Parasit Vectors       Date:  2022-06-20       Impact factor: 4.047

2.  Tuberculosis infection control measures in healthcare facilities in Moyen-Ogooué Province, Gabon.

Authors:  Anja Vigenschow; Bayodé Romeo Adegbite; Jean-Ronald Edoa; Abraham Alabi; Akim A Adegnika; Martin P Grobusch; Marguerite Massinga-Loembe
Journal:  BMC Health Serv Res       Date:  2021-11-05       Impact factor: 2.655

3.  Non-communicable disease co-morbidity and associated factors in tuberculosis patients: A cross-sectional study in Gabon.

Authors:  B R Adegbite; J R Edoa; Jbp Agbo Achimi Abdul; M Epola; C Mevyann; J C Dejon-Agobé; J F Zinsou; Y J Honkpehedji; S G Mpagama; A S Alabi; P G Kremsner; K Klipstein-Grobusch; A A Adegnika; M P Grobusch
Journal:  EClinicalMedicine       Date:  2022-02-27

4.  Performance of Field's Stain Compared with Conventional Giemsa Stain for the Rapid Detection of Blood Microfilariae in Gabon.

Authors:  Franck-A Ekoka Mbassi; Ghyslain Mombo-Ngoma; Wilfrid Ndzebe Ndoumba; Emmanuel K Yovo; Kirsten A Eberhardt; Dorothea Ekoka Mbassi; Ayôla A Adegnika; Selidji T Agnandji; Marielle K Bouyou-Akotet; Michael Ramharter; Rella Zoleko-Manego
Journal:  Am J Trop Med Hyg       Date:  2022-07-05       Impact factor: 3.707

5.  Effectiveness of pyronaridine-artesunate against Plasmodium malariae, Plasmodium ovale spp, and mixed-Plasmodium infections: a post-hoc analysis of the CANTAM-Pyramax trial.

Authors:  Mirjam Groger; Gaston Tona Lutete; Ghyslain Mombo-Ngoma; Nsengi Y Ntamabyaliro; Gauthier Kahunu Mesia; Trésor Bodjick Muena Mujobu; Lia Betty Dimessa Mbadinga; Rella Zoleko Manego; Diane Egger-Adam; Isabelle Borghini-Fuhrer; Jangsik Shin; Robert Miller; Sarah Arbe-Barnes; Stephan Duparc; Michael Ramharter
Journal:  Lancet Microbe       Date:  2022-05-30

6.  Pilot Malacology Surveys for the Intermediate Hosts of Schistosomiasis in Rural and Semi-Urban Areas of the Moyen-Ogooué Province, Gabon.

Authors:  Jean Claude Dejon Agobé; Henry Curtis Kariuki; Jeannot Fréjus Zinsou; Yabo Josiane Honkpehedji; Martin Peter Grobusch; Ayola Akim Adegnika
Journal:  Trop Med Infect Dis       Date:  2021-12-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.